Ian A.W. Howes

Managing Director and Chief Financial Officer

Ian A.W. Howes joined ALSP as Managing Director and Chief Financial Officer in October 2017, bringing over 20 years of experience in senior financial roles developing early stage life sciences companies. Mr. Howes oversees the firm’s financial, legal, and operations functions. He works closely with all ALSP I portfolio companies overseeing capital markets activities and providing day-to-day financial and strategic direction. During his career, he has completed numerous rounds of private and public equity and debt transactions, including two initial public offerings. He also has successfully managed multiple M&A transactions for companies where he served as CFO, including the sale of Scioderm to Amicus Therapeutics in 2015 and the sale of Serenex to Pfizer in 2008.

Prior to ALSP, Mr. Howes served as CFO of Heart Metabolics, a venture capital backed biopharmaceutical company developing drugs for cardiovascular diseases. Prior to that he served as CFO of Scioderm, a pediatric orphan disease company, where, in 2015, he managed the sale of the company to Amicus Therapeutics (NASDAQ: FOLD). Prior to that, Mr. Howes served as CFO for Akebia Therapeutics (NASDAQ: AKBA), a biotechnology company developing pharmaceutical drugs for anemia and ophthalmology. Before Akebia, Mr. Howes served as CFO and Senior VP of Corporate Development of Serenex, an integrated discovery and development-stage oncology company where, in 2008, he managed the sale of the company to Pfizer. Prior to Serenex, Mr. Howes served as CFO and VP Operations at Paradigm Genetics (Nasdaq: PDGM).

Mr. Howes began his professional career with Coopers & Lybrand in London and is a Chartered Accountant. He received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and has a B.S. in Accounting and Finance from the University of Warwick.